This clinical trial is focused on studying the treatment of migraine in children aged 6 to 17. The treatment being tested is a medication called lasmiditan, which is taken as a tablet. The purpose of the study is to evaluate the safety and tolerability of using lasmiditan over a long period for treating migraine attacks in young patients.

Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.